About ProQR Therapeutics NV
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: NL
- Website: https://www.proqr.com/
Frequently Asked Questions
What is the 52-week range for PRQR?
The 52-week high is $3.1 and the 52-week low is $1.33.
What is the P/E ratio for PRQR?
The P/E ratio data is currently unavailable.
What is the dividend yield for PRQR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -75.23%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -228.18%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.83.
Analyst Recommendation Trends
Wall Street analyst consensus for PRQR over the last few months:
Latest PRQR News
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
ProQR Therapeutics (NASDAQ:PRQR) said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is developing NTCP programs for cholestatic liver diseases, initially focusing on
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8
HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow
2026-09-30. The following slide deck was published by ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call September 30, 2026 11:00 AM EDTCompany ParticipantsSarah Kiely - Vice President of Investor...
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
Appointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipelineAX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027ProQR’s expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development pro
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. AX-0811 is ProQR’s next-generation, AI-discovered investigational RNA editing oligon
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-31 | de Boer Daniel Anton | +200,000 | $1.7698 | $353,960 |
| 2026-07-17 | Filius Bart | +150,000 | $1.7195 | $257,925 |
| 2026-07-09 | de Boer Daniel Anton | +150,000 | $1.74 | $261,000 |
| 2026-07-07 | de Boer Daniel Anton | +150,000 | $1.59 | $238,500 |
| 2026-06-02 | Hinsch Gylvin Lykke | +14,495 | - | - |